AUR PRO
Clinical Information and Biospecimen Collection from Patients with Recurrent or Stage IV Breast Cancer

Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Georgetown University, Johns Hopkins University, Mayo Clinic Cancer Center, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of California San Francisco, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Pennsylvania, University of Pittsburgh Cancer Institute, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center, Vanderbilt University

TBCRC 037
A Trial of Endocrine Response in Patients with Invasive Lobular Carcinoma

Baylor College of Medicine, Georgetown University, Mayo Clinic Cancer Center, Montefiore Medical Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of North Carolina at Chapel Hill / Lineberger Cancer Center, University of Pennsylvania, University of Pittsburgh Cancer Institute, University of Washington School of Medicine/Fred Hutchinson Cancer Center

Relevant Publications/Presentations: 2015 SABCS Poster

TBCRC 042
A Randomized Phase II Window-of-opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions

Baylor College of Medicine, Indiana University Simon Cancer Center, MD Anderson Cancer Center, Montefiore Medical Center, University of Alabama at Birmingham, University of North Carolina at Chapel Hill, Vanderbilt University

TBCRC 044
A Randomized Phase II Study of Pembrolizumab, an anti-PD (programmed cell death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease

Dana-Farber/ Harvard Cancer Center, Georgetown University, Indiana University Simon Cancer Center, University of California San Francisco, University of Chicago Medical Center, University of Pittsburgh Cancer Institute, Vanderbilt University

Relevant Publications/Presentations: 2021 ASCO Poster; 2020 SABCS Poster; 2020 ASCO Poster; 2019 SABCS Poster; 2018 SABCS Poster; 2018 ASCO Poster; 2017 SABCS Poster

TBCRC 046
Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY)

Dana-Farber/ Harvard Cancer Center, Georgetown University, Indiana University Simon Cancer Center, University of Chicago Medical Center, University of Pennsylvania, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center, Vanderbilt University

TBCRC 047
Avelumab with Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients with Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)

Baylor, Dana-Farber/ Harvard Cancer Center, Duke, Georgetown University, Johns Hopkins University, Mayo Clinic Cancer Center, Montefiore Medical Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of California San Francisco, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Pennsylvania, Vanderbilt University

TBCRC 048
Olaparib in Metastatic Breast Cancer

Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Indiana University Simon Cancer Center, Johns Hopkins University, Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham, University of California San Francisco, University of Chicago Medical Center, University of Pennsylvania, University of Pittsburgh Cancer Institute, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center

Relevant Publications/Presentations: 2020 ASCO Talk; 2020 JCO Publication

TBCRC 050
Niraparib in Combination with Trastuzumab in Metastatic HER2+ Breast Cancer

Mayo Clinic Cancer Center, Montefiore Medical Center,  University of Alabama at Birmingham, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Pennsylvania, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center

Relevant Publications/Presentations: 2021 ASCO Poster

TBCRC 051
Estradiol in Treating Patients with ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Georgetown University, Mayo Clinic Cancer Center, Montefiore Medical Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of California San Francisco, University of Chicago Medical Center, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center

TBCRC 052
MARGetuximab Or Trastuzumab (MARGOT)

Baylor College of Medicine, Dana-Farber/ Harvard Cancer Center, Georgetown University, MD Anderson Cancer Center, Montefiore Medical Center, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Pittsburgh Cancer Institute, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center

TBCRC 053
Pre-operative Pembrolizumab + Radiation Therapy in Breast Cancer

Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Indiana University Simon Cancer Center, Johns Hopkins University, Mayo Clinic Cancer Center, MD Anderson Cancer Center, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, University of North Carolina at Chapel Hill

TBCRC 054
Exercise Treatment with Standard Therapy for Metastatic Breast Cancer

Indian University Simon Cancer Center, Montefiore Cancer Center, Memorial Sloan Kettering Cancer Center

TBCRC 055
Radiation, Immunotherapy, and PARP Inhibitor in Triple Negative Breast Cancer (NADiR)

Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Johns Hopkins University, University of Pennsylvania

TBCRC 056
Niraparib + TSR042 in BRCA Mutated Breast Cancer

Dana-Farber/ Harvard Cancer Center, Johns Hopkins University, Mayo Clinic Cancer Center, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center, Vanderbilt University, Yale University

TBCRC 059
ETHAN - Endocrine Therapy for Male Breast Cancer

Dana-Farber/ Harvard Cancer Center, Georgetown University, Indiana University Simon Cancer Center, Mayo Clinic Cancer Center, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, University of Pittsburgh, University of Pennsylvania, University of North Carolina at Chapel Hill

TBCRC 061
Biomarker Analysis of Patients with Breast Cancer Receiving Immunotherapy

Baylor College of Medicine, Montefiore Medical Center, University of Chicago Medical Center, University of North Carolina at Chapel Hill, Vanderbilt University

TBCRC 062
STOP-HER2: Stopping Trastuzumab in HER2+ MBC

Baylor College of Medicine, Dana-Farber/ Harvard Cancer Center, Duke University Medical Cancer Center, Georgetown University, Indiana University Simon Cancer Center, Mayo Clinic Cancer Center, Memorial Sloan Kettering Cancer Center, University of Pittsburgh, Vanderbilt University, University of Washington School of Medicine/ Fred Hutchinson Cancer Research Center